609789-06-2

Usage

Type of compound

Pyrrolidine derivative

Protecting group

BOC (tert-butyloxycarbonyl) at the nitrogen atom

Functional group

4-cyanophenylamino

Common use

Intermediate in the synthesis of various pharmaceuticals and organic compounds

Application in pharmaceuticals

Common functional group in many pharmaceutical compounds

Protecting group purpose

To protect amine groups from unwanted reactions and allow for selective deprotection under specific conditions

Value in organic synthesis

Versatile reactivity

Value in drug development

Potential pharmacological properties

Upstream product

• 1194-02-1 4-fluorobenzonitrile 
• 147081-44-5 (3S)-3-amino-1-(tert-butoxycarbonyl)-pyrrolidine 
• 940865-64-5 1,1-dimethylethyl (3S)-3-[(3-chloro-4-cyanophenyl)amino]-1-pyrrolidnecarboxylate 
• 141699-57-2 3-methanesulfonyloxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 113451-52-8 tert-butyl ester of 3-azidopyrrolidine-1-carboxylic acid 
• 103057-44-9 N-(tert-butoxycarbonyl)-3-hydroxypyrrolidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 623-00-7 4-bromobenzenecarbonitrile 
• 186550-13-0 3-amino-1-(t-butoxycarbonyl)pyrrolidine 

Relevant academic research and scientific papers

HISTONE DEACETYLASE INHIBTORS

Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).

PYRROLIDINEANILINES

The present invention relates to a compotind represented by the following formula I or a pharmaceutically acceptable salt thereof; wherein R1, R2, and y are defined herein. The present invention further relates to compositions that include the compound of the present invention as well as a method of treating a patient from endometreosis or uterine fibroids.

BENZAMIDE DERIVATIVES

A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R1, R2, R3 and R4, which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na+/H+ exchange transport system caused by the Rho kinase inhibition, for example, hypertension.

Palladium-mediated arylation of 3-aminopiperidines and 3-aminopyrrolidines

This paper describes the palladium-catalyzed arylation of 1-substituted 3-aminopyrrolidines or piperidines. Palladium(0) (1-2 mol %) in conjunction with "Buchwald's ligand" [2-(dimethylamino)-2′- (dicyclohexylphosphine)biphenyll was shown to be the catalyst of choice for the coupling with aryl bromides or chlorides. When bromobenzene was used, a strong temperature effect was noticed. Whereas no reaction occurred at 100 °C, yields higher than 85% were obtained at 130 °C for each substrate. Such an effect was not observed when diphosphines were used. Whereas Xantphos and, to a lesser extent BINAP, were moderately efficient in the coupling of all diamines, the palladium-mediated arylation in the presence of monophosphines was strongly dependent on the substrate. The results suggest the participation of both nitrogens of the aminoheterocycle in the reactive intermediate. This participation could also account for the highly selective arylation of the endocyclic nitrogen of unsubstituted 3-aminopyrrolidine or piperidine. Optimal conditions were found for the arylation using 2- or 4-substituted electron-poor or enriched aryl halides.